# Evaluation of Efficacy and Safety of the Concomitant of RUTI® Immunotherapy With the Standard Treatment in TB Patients

> **NCT05136833** · PHASE2 · WITHDRAWN · sponsor: **Archivel Farma S.L.**

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** RUTI® vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05136833
- **Lead sponsor:** Archivel Farma S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Covid-19 pandemia
- **Last updated:** 2022-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05136833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05136833, "Evaluation of Efficacy and Safety of the Concomitant of RUTI® Immunotherapy With the Standard Treatment in TB Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05136833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*